论文部分内容阅读
目的:探讨乌司他丁治疗脓毒血症患者的临床疗效。方法:将2012年1月至2016年7月在我院48例脓毒血症患者患者按随机数字表法分为治疗组和对照组各24例,对照组抗感染、杀菌、肠内营养支持、调节电解质等对症治疗,治疗组加加用乌司他丁,30万U每天3次,在治疗后3d、7d后观察两组APACHEⅡ评分及PCT水平。结果:两组患者治疗后APACHEⅡ评分均显著低于治疗前,且治疗后治疗组患者APACHEⅡ评分较对照组更低(P<0.05),治疗组的预后明显优于对照组(P<0.05),治疗组于治疗后第3、7天血清PCT逐渐下降,均低于治疗前和对照组治疗后(P<0.05)。结论:乌司他丁在脓毒血症临床治疗中疗效是可靠的,值得继续应用。
Objective: To investigate the clinical efficacy of ulinastatin in patients with sepsis. Methods: From January 2012 to July 2016, 48 patients with sepsis in our hospital were randomly divided into treatment group (24 cases) and control group (24 cases). The control group received anti-infection, sterilization and enteral nutrition support , Adjust the electrolyte and other symptomatic treatment, the treatment group plus ulinastatin, 30 million U 3 times a day, 3d, 7d after treatment, two groups were observed APACHE Ⅱ score and PCT levels. Results: The APACHE Ⅱ scores of the two groups were significantly lower than those before treatment (P <0.05), and the APACHEⅡ scores of the treatment group were lower than those of the control group (P <0.05). The prognosis of the treatment group was significantly better than that of the control group (P <0.05) The PCT of the treatment group decreased gradually on the 3rd and 7th day after treatment, both of which were lower than those before treatment and after the control group (P <0.05). Conclusion: Ulinastatin is effective in clinical treatment of sepsis and is worthy of continuous application.